A Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab
Latest Information Update: 12 Apr 2023
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Acronyms PROSPERO
- Sponsors Roche
- 27 Feb 2023 Results of post of analysis assessing the respiratory related patient reported outcomes (Asthma Quality of Life Questionnaire, mini Rhino-conjunctivitis Quality of Life Questionnaire stratified by where they fell on the omalizumab dosing table, presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 14 Nov 2022 Results of post hoc analysis examined data from the IA05 (NCT00079937) and PROSPERO (NCT01922037), presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology.
- 14 Nov 2022 Post hoc analysis results presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology